Nuvoton Releases 1.7 W 420 nm Indigo Laser Diode

KYOTO,Japan,Jan. 23,2025-- Nuvoton Technology Corporation Japan (hereinafter "NTCJ") announced on January 15 the launch of its industry-leading (*) indigo semiconductor laser,which emits an

Focus

Jan 26, 2025

Akkodis Acquires Raland Compliance Partners and Expands Life Sciences Consulting Capabilities

The acquisition will further strengthen the global Smart Industry leader\'s footprint in the Life Sciences industry,enabling it to provide clients with enhanced services offerings.

Focus

Jan 26, 2025

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC

CHENGDU,China,Jan. 23,2025--Sichuan Kelun-Biotech Biopharmaceutical Co.,Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Produc

Focus

Jan 26, 2025

Haier Lights up the Australian Open: A Landmark Partnership Celebrating Innovation and Excellence

MELBOURNE,Australia,Jan. 23,2025-- The Australian Open ("AO"),one of the world\'s premier Grand Slam tennis tournaments,is underway at Melbourne Park starting from January 6. Haier,a global

Focus

Jan 26, 2025

Willog to Showcase Its Logistics Intelligence Solutions at Manifest 2025

LAS VEGAS,Jan. 23,2025-- Willog (www.willog.io),a leading provider of IoT-based logistics intelligence solutions,today announced its participation in Manifest 2025,a premier international logistics ev

Focus

Jan 26, 2025

E-POWER leads global market innovation with LED power supplies

SEOUL,South Korea,Jan. 23,2025-- E-POWER CO.,LTD,a company specializing in the design and production of LED power supplies,is attracting attention in the global market for its ultra-slim,high-efficien

Focus

Jan 26, 2025

Focus

Nuvoton Releases 1.7 W 420 nm Indigo Laser Diode

Akkodis Acquires Raland Compliance Partners and Expands Life Sciences Consulting Capabilities

Kelun-Biotech&#039;s Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC

Haier Lights up the Australian Open: A Landmark Partnership Celebrating Innovation and Excellence

Willog to Showcase Its Logistics Intelligence Solutions at Manifest 2025

E-POWER leads global market innovation with LED power supplies

Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC